Rate of clinical progression in Parkinson's disease. A prospective study

被引:129
作者
Schrag, Anette [1 ]
Dodel, Richard
Spottke, Annika
Bornschein, Bernhard
Siebert, Uwe
Quinn, Niall P.
机构
[1] UCL, Dept Clin Neurosci, Royal Free Hosp, London NW3 2PF, England
[2] UCL, Dept Motor Neurosci & Movement Disorders, Inst Neurol, London, England
[3] Univ Marburg, Dept Neurol, Marburg, Germany
[4] UMIT Univ Hlth Sci Med Informat & Technol, Hall, Germany
[5] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA
关键词
Parkinson's disease; progression; UPDRS; scales;
D O I
10.1002/mds.21429
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Few prospective data on the clinical progression of Parkinson's disease (PD) in patient groups outside treatment trials in selected patients are available, and controversy exists on the rate of clinical disease progression with advancing disease. In this study, we investigated the rate of clinical progression of PD in a clinic-based sample of 145 patients over 1 year and in a community-based sample of 124 patients over 4 years. Depending on the sample and clinical scale used, mean deterioration of motor and disability scores ranged from 2.4 to 7.4% of the maximum possible score per year, and standard deviations indicated that there was considerable variability of progression rates between individuals. The progression of motor scores decreased with follow-up over 4 years and significantly decreased in more advanced disease stages. Deterioration of disability scores did not differ between disease stages; this may reflect the increasing rate of disease complications, which contribute to increasing disability in addition to motor impairment alone, in more advanced disease. Thus, motor fluctuations, hallucinations, depression, memory problems, and bladder symptoms were all reported more often at follow-up in the community-based sample (all P < 0.01), and dyskinesias, motor fluctuations, falls, and hallucinations were more common and cognitive and depression scores worse in higher disease stages in the clinic-based sample (all P < 0.001). We conclude that progression of motor scores in PD decreases with advancing disease in PD. However, disability continues to deteriorate with advancing disease and with the development of disease complications that are likely to be related to additional extrastriatal pathology. (C) 2007 Movement Disorder Society.
引用
收藏
页码:938 / 945
页数:8
相关论文
共 50 条
  • [21] Amimia in Parkinson's disease. Significance and correlation with the clinical features
    Garcia-Ruiz, Pedro J.
    Feliz-Feliz, Cici E.
    Maycas-Cepeda, Teresa
    del Val-Fernandez, Javier
    REVISTA DE NEUROLOGIA, 2018, 66 (02) : 45 - 48
  • [22] Pain in Parkinson's disease.
    Giuffrida, R
    Vingerhoets, FJG
    Bogousslavsky, J
    Ghika, J
    REVUE NEUROLOGIQUE, 2005, 161 (04) : 407 - 418
  • [23] Cognitive decline in Parkinson's disease: A prospective longitudinal study
    Muslimovic, Dino
    Post, Bart
    Speelman, Johannes D.
    de Haan, Rob J.
    Schmand, Ben
    JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2009, 15 (03) : 426 - 437
  • [24] The effect of ischemic cerebrovascular disease on the clinical characteristics of Parkinson's disease. A post-mortem study
    Papapetropoulos, S
    Gonzalez, J
    Mash, DC
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (01) : 96 - 97
  • [25] Volumetric changes and clinical trajectories in Parkinson’s disease: a prospective multicentric study
    Ana Marques
    Elise Macias
    Bruno Pereira
    Elodie Durand
    Carine Chassain
    Tiphaine Vidal
    Luc Defebvre
    Nicolas Carriere
    Valerie Fraix
    Elena Moro
    Stéphane Thobois
    Elise Metereau
    Graziella Mangone
    Marie Vidailhet
    Jean-Christophe Corvol
    Stéphane Lehéricy
    Nicolas Menjot de Champfleur
    Christian Geny
    Umberto Spampinato
    Wassilios G. Meissner
    Solène Frismand
    Emmanuelle Schmitt
    Anne Doé de Maindreville
    Christophe Portefaix
    Philippe Remy
    Gilles Fénelon
    Jean Luc Houeto
    Olivier Colin
    Olivier Rascol
    Patrice Peran
    Jean-Marie Bonny
    Maria Livia Fantini
    Franck Durif
    Journal of Neurology, 2023, 270 : 6033 - 6043
  • [26] Prospective Study of Lung Function with Prodromal, Clinical Parkinson's Disease, and Mortality
    Chen, Xiao
    Zhang, Zhicheng
    Tong, Lin
    Wang, Han
    Xu, Xinming
    Sun, Liang
    Li, Yaqi
    Gao, Xiang
    JOURNAL OF PARKINSONS DISEASE, 2024, 14 (07) : 1427 - 1439
  • [27] Progression of Fatigue in Early Parkinson's Disease: A 3-Year Prospective Cohort Study
    Ou, Ruwei
    Hou, Yanbing
    Liu, Kuncheng
    Lin, Junyu
    Jiang, Zheng
    Wei, Qianqian
    Zhang, Lingyu
    Cao, Bei
    Zhao, Bi
    Song, Wei
    Shang, Huifang
    FRONTIERS IN AGING NEUROSCIENCE, 2021, 13
  • [28] Rate of motor progression in Parkinson's disease: a systematic review and meta-analysis
    Pauwels, Ayla
    Phan, Albert L. G.
    Ding, Catherine
    Phan, Thanh G.
    Kempster, Peter A.
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [29] Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson’s disease: a prospective cohort study
    Junyu Lin
    Ruwei Ou
    Chunyu Li
    Yanbing Hou
    Lingyu Zhang
    Qianqian Wei
    Dejiang Pang
    Kuncheng Liu
    Qirui Jiang
    Tianmi Yang
    Yi Xiao
    Bi Zhao
    Xueping Chen
    Wei Song
    Jing Yang
    Ying Wu
    Huifang Shang
    BMC Medicine, 21
  • [30] Plasma glial fibrillary acidic protein as a biomarker of disease progression in Parkinson's disease: a prospective cohort study
    Lin, Junyu
    Ou, Ruwei
    Li, Chunyu
    Hou, Yanbing
    Zhang, Lingyu
    Wei, Qianqian
    Pang, Dejiang
    Liu, Kuncheng
    Jiang, Qirui
    Yang, Tianmi
    Xiao, Yi
    Zhao, Bi
    Chen, Xueping
    Song, Wei
    Yang, Jing
    Wu, Ying
    Shang, Huifang
    BMC MEDICINE, 2023, 21 (01)